This article is more than 5 years old. Information may no longer be current.

NeoVista receives European approval for wet AMD treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

FREMONT, Calif. — NeoVista has received approval from European authorities to market its focal epiretinal brachytherapy device throughout the European Union as a treatment for wet age-related macular degeneration, the company announced.

Using strontium 90, the focal epiretinal brachytherapy device delivers beta radiation to leaking blood vessels affecting central vision, without damaging surrounding tissues.

As a result of the targeted radiation delivery, preliminary data show that the procedure can be safe for both the physician and the patient, and may restore some vision, according to a press release from the company.